Why Grace Therapeutics, Inc.’s (GRCE) Stock Is Up 6.03%
As of Thursday, April 23, Grace Therapeutics, Inc.’s GRCE share price has surged by 6.03%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Commentary & Analysis
Why Grace Therapeutics, Inc.’s (GRCE) Stock Is Down 7.44%
As of Wednesday, April 22, Grace Therapeutics, Inc.’s GRCE share price has dipped by 7.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Grace Therapeutics, Inc.’s (GRCE) Stock Is Down 10.73%
As of Wednesday, April 22, Grace Therapeutics, Inc.’s GRCE share price has dipped by 10.73%, which has investors questioning if this is right time to buy.Tudor Pop
Why Grace Therapeutics, Inc.’s (GRCE) Stock Is Up 7.94%
As of Wednesday, April 15, Grace Therapeutics, Inc.’s GRCE share price has surged by 7.94%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Grace Therapeutics, Inc.’s (GRCE) Stock Is Up 7.07%
As of Tuesday, April 14, Grace Therapeutics, Inc.’s GRCE share price has surged by 7.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | GRCE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $33.8 | $579.1 | 13% |
|
| Shares Out (Mil) | 17.3 | 43.0 | 28% |
|
| Institutional Ownership | 62.7% | 84.3% | 40% |
|
| Float (Mil) | 13.6 | 46.8 | 23% |
|
| Beta | 0.37 | 0.62 | 21% |
|
| Avg Daily Volume (000s) | 300 | 285 | 51% |
|
| Price Change (52-week) |
(30.0%) | 63.8% | 25% |
|
| Growth | GRCE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 16.9% | (1.4%) | 67% |
|
| EPS (5yr) | 43.2% | 14.9% | 90 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (14.9%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | na | |
| Current EPS | ($0.131) | ($0.525) | na | |
| Month Ago EPS | ($0.131) | ($0.525) | na | |
| # Rev Up | 0 | 0 | na | |
| # Rev Down | 1 | 1 | na | |
| Three Months Ago EPS | ($0.146) | ($0.678) | na | |
| Year/Year Chg | 92.6% | 11.2% | (172.2%) | |
| Financials | GRCE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 31% |
|
| EPS (TTM) | ($0.472) | ($0.500) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($6) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $24 | $522 | 12% |
|
| Valuation | GRCE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.52 | 2.73 | 9% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | GRCE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (11.2%) | (24.6%) | 25% |
|
| ROE | (11.9%) | (19.7%) | 27% |
|
| Liabilities to Assets | 4.1% | 35.5% | 2% |
|
| F-Score | 1 | 3 | 1% |
|
Grace Therapeutics, Inc. did not pass any screens on 7/31/2026.
